Your browser is no longer supported. Please, upgrade your browser.
Settings
PTX Pernix Therapeutics Holdings, Inc. daily Stock Chart
PTX [NASD]
Pernix Therapeutics Holdings, Inc.
Index- P/E- EPS (ttm)-6.39 Insider Own1.10% Shs Outstand12.92M Perf Week3.88%
Market Cap4.43M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.92M Perf Month-39.47%
Income-76.60M PEG- EPS next Q- Inst Own20.60% Short Float16.54% Perf Quarter-61.81%
Sales127.90M P/S0.03 EPS this Y66.70% Inst Trans34.05% Short Ratio3.81 Perf Half Y-85.83%
Book/sh-15.40 P/B- EPS next Y- ROA-37.10% Target Price30.00 Perf Year-85.60%
Cash/sh1.90 P/C0.18 EPS next 5Y4.00% ROE39.30% 52W Range0.27 - 3.30 Perf YTD-85.72%
Dividend- P/FCF- EPS past 5Y-18.69% ROI-39.30% 52W High-89.61% Beta1.30
Dividend %- Quick Ratio0.90 Sales past 5Y19.00% Gross Margin68.80% 52W Low28.39% ATR0.12
Employees171 Current Ratio1.10 Sales Q/Q-8.10% Oper. Margin-38.00% RSI (14)39.85 Volatility33.76% 31.71%
OptionableYes Debt/Eq- EPS Q/Q-331.30% Profit Margin-59.70% Rel Volume0.92 Prev Close0.38
ShortableYes LT Debt/Eq- EarningsNov 13 AMC Payout- Avg Volume561.51K Price0.34
Recom3.00 SMA20-24.98% SMA50-46.68% SMA200-80.25% Volume516,659 Change-10.94%
Aug-12-16Downgrade Brean Capital Buy → Hold
Mar-11-16Downgrade Needham Buy → Hold
Mar-08-16Reiterated Needham Strong Buy $10 → $8
Sep-09-15Resumed JMP Securities Mkt Outperform
Aug-07-15Reiterated Needham Strong Buy $12 → $10
Aug-07-15Reiterated Brean Capital Buy $17 → $14
Jun-29-15Initiated Brean Capital Buy $17
Apr-28-15Reiterated Needham Strong Buy $16 → $12
Apr-22-15Initiated Piper Jaffray Overweight $14
Mar-26-15Initiated Oppenheimer Outperform $15
Feb-26-15Reiterated Needham Strong Buy $12 → $16
Nov-11-14Reiterated Needham Strong Buy $10 → $12
May-27-14Upgrade Aegis Capital Hold → Buy
May-15-14Upgrade Needham Buy → Strong Buy $6.30 → $10
Nov-13-13Reiterated Needham Buy $6 → $5
Oct-21-13Downgrade Aegis Capital Buy → Hold $3
Jul-26-13Downgrade Cantor Fitzgerald Hold → Sell $3 → $2.50
May-15-13Reiterated Cantor Fitzgerald Hold $7 → $3
May-14-13Reiterated Needham Buy $8 → $6
Mar-19-13Reiterated Needham Buy $11 → $8
Nov-30-18 10:42AM  Is Pernix Therapeutics Holdings Incs (NASDAQ:PTX) CEO Overpaid Relative To Its Peers? Simply Wall St. -8.35%
Nov-13-18 07:35AM  Detailed Research: Economic Perspectives on Pernix Therapeutics, Hallador Energy, Vince Holding, Tuesday Morning, Information Services Group, and Sienna Biopharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire -7.46%
Nov-09-18 05:16AM  Edited Transcript of PTX earnings conference call or presentation 8-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -16.21%
Nov-08-18 05:07PM  Pernix Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Pernix® Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-02-18 08:00AM  Pernix Therapeutics to Report Third Quarter 2018 Financial Results on Thursday, November 8 GlobeNewswire
Sep-26-18 02:39PM  Why You Need To Look At This Factor Before Buying Pernix Therapeutics Holdings Inc (NASDAQ:PTX) Simply Wall St.
Sep-12-18 07:00AM  Pernix Therapeutics Holdings, Inc.s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek® GlobeNewswire
Sep-11-18 12:12PM  Edited Transcript of PTX earnings conference call or presentation 9-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-27-18 08:00AM  Pernix Therapeutics Announces Ruling in Patent Litigation Concerning Zohydro® ER with BeadTek® GlobeNewswire -11.85%
Aug-09-18 04:01PM  Pernix Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-01-18 09:08AM  Pernix Therapeutics Announces a Series of Transactions to Strengthen Its Balance Sheet and Improve Financial Flexibility GlobeNewswire
Jul-31-18 04:15PM  Pernix Therapeutics to Report Second Quarter 2018 Financial Results on Thursday, August 9 GlobeNewswire
Jul-30-18 08:00AM  Pernix Therapeutics Announces Successful Closing of Transaction Regarding Worldwide Rights to Contrave® for Weight Loss GlobeNewswire
Jun-22-18 08:00AM  Pernix Therapeutics Announces Result of Bid Process for Acquisition of Worldwide Rights to Contrave® for Weight Loss GlobeNewswire
May-17-18 09:42PM  Edited Transcript of PTX earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 04:01PM  Pernix Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 02:34PM  Should You Worry About Pernix Therapeutics Holdings Incs (NASDAQ:PTX) CEO Pay Check? Simply Wall St.
May-01-18 04:05PM  Pernix Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 10 GlobeNewswire
Apr-23-18 11:30AM  Pernix Therapeutics Announces Participation in Lead Bid for Acquisition of Worldwide Rights to Contrave® for Weight Loss GlobeNewswire
Apr-11-18 11:43AM  One Thing To Consider Before Buying Pernix Therapeutics Holdings Inc (NASDAQ:PTX) Simply Wall St.
Apr-06-18 07:30AM  Wired News Amarins REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACE ACCESSWIRE
Mar-27-18 08:00AM  Pernix Therapeutics Announces Return to Market of Zohydro® ER with BeadTek® 20 mg GlobeNewswire
Mar-20-18 08:22AM  Why Pernix Therapeutics Holdings Incs (NASDAQ:PTX) Ownership Structure Is Important Simply Wall St.
Mar-09-18 10:06PM  Edited Transcript of PTX earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents -11.03%
Mar-08-18 04:01PM  Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire -10.77%
12:00PM  Pernix Therapeutics Holdings, Inc. to Host Earnings Call ACCESSWIRE
Feb-27-18 04:39PM  Where Pernix Therapeutics Holdings Inc (NASDAQ:PTX) Stands In Terms Of Earnings Growth Against Its Industry Simply Wall St.
Feb-22-18 04:05PM  Pernix Therapeutics to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 8 GlobeNewswire
Feb-16-18 04:01PM  Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Companys Subsidiary, Macoven Pharmaceuticals GlobeNewswire
Feb-06-18 04:05PM  Pernix Announces Appointment of Lead Independent Director and Key Management Team Promotion GlobeNewswire
Jan-29-18 08:00AM  Pernix Announces Patent Litigation Settlement Agreement with Actavis Concerning Zohydro® ER GlobeNewswire
Jan-05-18 08:30AM  Pernix Announces Reorganization of Sales Force to Focus on Zohydro® ER with BeadTek and Silenor® GlobeNewswire
Dec-19-17 01:49PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : December 19, 2017 Capital Cube +5.86%
Nov-29-17 12:08PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : November 29, 2017 Capital Cube
Nov-17-17 12:44PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : November 17, 2017 Capital Cube
Nov-16-17 08:30AM  Pernix Therapeutics Announces Election of Two Healthcare Industry Veterans to Board of Directors GlobeNewswire
Nov-14-17 07:44AM  Edited Transcript of PTX earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-13-17 08:41AM  Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 Capital Cube
Nov-10-17 10:29AM  Platinex Signs LOI to Acquire Interest in Cannabis-Infused Edible Brand and Co-Packing Facility in Oregon, Raising $600,000 in Private Placement - Video Hosted on InvestmentPitch.com Newsfile
Nov-07-17 04:01PM  Pernix Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
10:39AM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : November 7, 2017 Capital Cube
10:30AM  Pernix Therapeutics Holdings, Inc. to Host Earnings Call ACCESSWIRE
Nov-06-17 04:01PM  Pernix Therapeutics Announces Sale of Non-Core Product GlobeNewswire
Oct-31-17 07:05PM  Who Are The Largest Shareholders In Pernix Therapeutics Holdings Inc (PTX)? Simply Wall St.
Oct-26-17 08:00AM  Pernix Therapeutics to Report Third Quarter 2017 Financial Results on Tuesday, November 7 GlobeNewswire
Oct-18-17 07:40AM  Platinex Appoints Special Committee to Evaluate Cannabis Opportunities and Updates Its Cannabis Strategy GlobeNewswire
Oct-17-17 04:05PM  Pernix Therapeutics Announces Planned Departure of Chief Financial Officer GlobeNewswire
09:57AM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : October 17, 2017 Capital Cube
Aug-18-17 05:49PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : August 18, 2017 Capital Cube
Aug-12-17 07:55AM  Edited Transcript of PTX earnings conference call or presentation 27-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-17 05:03PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : August 8, 2017 Capital Cube
Aug-01-17 11:51AM  Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Capital Cube
Jul-27-17 04:01PM  Pernix Therapeutics Reports Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
12:00PM  Investor Network: Pernix Therapeutics Holdings, Inc. to Host Earnings Call ACCESSWIRE
Jul-20-17 04:54PM  Pernix Commences Refinancing Transactions to Fortify Balance Sheet GlobeNewswire
04:53PM  Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results GlobeNewswire
Jun-28-17 04:01PM  Pernix Therapeutics Added to Russell Microcap® Index GlobeNewswire
Jun-13-17 12:51PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : June 13, 2017 Capital Cube +5.71%
May-31-17 12:43PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 31, 2017 Capital Cube
May-21-17 06:54PM  Edited Transcript of PTX earnings conference call or presentation 15-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-19-17 09:30AM  Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 Capital Cube
May-16-17 12:58PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 16, 2017 Capital Cube -21.12%
May-15-17 04:01PM  Pernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
02:30PM  Investor Network: Pernix Therapeutics Holdings, Inc. to Host Earnings Call Accesswire
May-08-17 04:01PM  Pernix Therapeutics to Report First Quarter 2017 Financial Results on Monday, May 15 GlobeNewswire
May-04-17 04:15PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 4, 2017 Capital Cube +24.36%
May-01-17 08:00AM  Pernix Therapeutics Provides Update on Availability of Zohydro® ER with BeadTek 20mg Strength GlobeNewswire +5.04%
Apr-24-17 07:30AM  Rennova Health and Pernix Therapeutics Both Led In the Pharma Arena with Significant Share Price Jumps Accesswire
Apr-19-17 02:32PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : April 19, 2017 Capital Cube
Apr-18-17 04:00PM  Platinex Inc.-Proposed Private Placement Marketwired
Apr-07-17 05:19PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : April 7, 2017 Capital Cube +5.37%
Apr-05-17 08:41AM  Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017 Capital Cube -6.52%
08:41AM  Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
Apr-01-17 01:04PM  PERNIX THERAPEUTICS HOLDINGS, INC. Financials
Mar-30-17 09:30AM  Today's Research Reports on Biotech Stocks to Watch: Catalyst Biosciences and Pernix Therapeutics Accesswire
Mar-29-17 10:10AM  Tuesdays Top Biopharma Movers -13.05%
Mar-28-17 11:07PM  Edited Transcript of PTX earnings conference call or presentation 28-Mar-17 8:30pm GMT Thomson Reuters StreetEvents
11:07PM  Edited Transcript of PTX earnings conference call or presentation 28-Mar-17 8:30pm GMT
04:39PM  PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 10-K, Annual Report
04:01PM  Pernix Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Pernix Therapeutics Holdings Inc Earnings Release - After Market Close
Mar-23-17 04:44PM  Pernix: An Investor's Rationale to Staying Long GuruFocus.com
04:44PM  Pernix: An Investor's Rationale to Staying Long
Mar-16-17 12:14AM  Webcast-Q4 Earnings Call for Pernix Therapeutics Holdings, Inc. at Company Spotlight
Mar-15-17 04:01PM  Pernix Therapeutics to Report Fourth Quarter and Year-End 2016 Financial Results on Tuesday, March 28 GlobeNewswire
Feb-23-17 09:30AM  Biotech's Rise Shows No Sign of Slowing Dow in 2017: Today's Reports on Pernix Therapeutics and Brainstorm Cell Therapeutics Accesswire +19.70%
08:00AM  Pernix Therapeutics Prevails in Zohydro® ER ANDA Litigation GlobeNewswire
Feb-03-17 08:00AM  Pernix Therapeutics Provides Update on Arbitration GlobeNewswire -18.12%
Jan-20-17 01:51PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : January 20, 2017
Jan-06-17 04:01PM  Pernix Therapeutics Appoints Ken Piña as General Counsel and Chief Compliance Officer GlobeNewswire +28.65%
12:05PM  ETFs with exposure to Pernix Therapeutics Holdings, Inc. : January 6, 2017
Jan-05-17 09:55AM  Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q3, 2016 By the Numbers : January 5, 2017
Dec-07-16 08:15AM  Blog Coverage Teva Reports Positive Outcome for the European Label for COPAXONE®; Replaces Generics Head Accesswire
Nov-29-16 04:06PM  PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Nov-22-16 06:36AM  PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statement
06:30AM  Pernix Therapeutics Appoints New Board Member GlobeNewswire
Nov-10-16 04:46PM  PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report
04:01PM  Pernix Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
07:07AM  Q3 2016 Pernix Therapeutics Holdings Inc Earnings Release - After Market Close
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.